Dr Prem Mahendra is the leading private consultant haemato-oncologist in the West Midlands. For more than 25 years she has been providing an unparalleled, empathetic and efficient service for patients with blood cancer, and is passionate about delivering outstanding care. Private patients are seen either at the Priory Hospital, Edgbaston, Birmingham or at the HCA Harborne Hospital, Edgbaston, Birmingham.
She is an NHS consultant at the Queen Elizabeth Hospital, Birmingham.
Areas of expertise are care of patients with:
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Myeloma
- Acute myeloid and lymphoblastic leukaemia
- Chronic lymphocytic and myeloid leukaemia
- Myelodysplasia
- Myeloproliferative disorder
- Waldenstroms macroglobulinaemia
And those undergoing:
- Autologous stem cell transplantation
- Allogeneic stem cell transplantation.
- CAR-T (chimeric antigen receptor-T-cell therapy)
![](https://premmahendra.co.uk/wp-content/uploads/2021/05/Blood_Cancer_UK.jpg)
![](https://premmahendra.co.uk/wp-content/uploads/2021/05/MyelomaUK.jpg)
![Lymphoma_Action](https://premmahendra.co.uk/wp-content/uploads/2021/05/Lymphoma_Action.jpg)
Latest News
Updates from American Society of Hematology Meeting 2023
Myeloma – the phase 3 PERSEUS trial from the European Myeloma Network randomised approximately 700 newly diagnosed patients with myeloma to treatment with dartumumab, velcade...
Priory Hospital treats first patient with Teclistamab a bispecific antibody treatment for myeloma.
Bispecific T-cell engagers are a new and innovative treatment for myeloma. Two bispecific antibodies Teclistamab and Talquetamab have been approved by the EMA for the...
Exciting new treatment for diffuse-large B-cell lymphoma approved by the European Medicines Agency (EMA).
In July 2023 the EMA approved Glofitamab, one of the most potent single drugs available for the treatment of relapsed/refractory DLBCL. Glofitamab is a CD20xCD3...